Ollin Biosciences Launches with $100 Million to Advance Next-Generation Ophthalmic Therapies

Ollin Biosciences has emerged from stealth with $100 million in initial financing. Ollin is assembling a robust pipeline of both clinical and late-stage preclinical programs, building upon validated biologies to better address unmet treatment needs in ophthalmology.

“Our mission is to deliver best-in-disease therapies for patients whose sight is at risk,” said Jason Ehrlich, MD, PhD, co-founder and chief executive officer of Ollin. “With bispecific programs that address multiple disease pathways, we see tremendous opportunity to improve patient care in conditions where current treatments fall short.”

The funding round was led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital.

Ollin’s flagship program, OLN324, is a high-potency, high-molar-dose VEGF/Ang2 bispecific antibody now in phase 1b clinical development for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

• Study Status: More than 150 patients have been enrolled in the US-based JADE trial, a randomized phase 1b proof-of-concept study comparing OLN324 with faricimab

• Next Milestone: Topline results are anticipated in Q1 2026

• Differentiation Potential: OLN324’s higher anti-Ang2 potency, smaller protein format, and ability to be dosed at higher molar concentrations may enable extended durability and superior disease control

“Dual inhibition of VEGF and Ang2 could deliver more durable outcomes than VEGF blockade alone,” said Charles C. Wykoff, MD, PhD, chairman of research at Retina Consultants of America. Early single and multiple-dose studies in China have already demonstrated encouraging vision gains and a favorable safety profile.

Ollin’s second candidate, OLN102, is a first-in-class TSHR/IGF-1R bispecific antibody for thyroid eye disease (TED) and underlying Graves’ disease. By simultaneously targeting two clinically validated receptors involved in TED pathogenesis, OLN102 aims to improve both efficacy and safety compared to existing options. Clinical development is expected to begin in 2026.

Ollin brings together seasoned ophthalmology drug developers and prominent life sciences investors:

Leadership Team:

• Jason Ehrlich, M.D., Ph.D., co-founder and chief executive officer

• Andrew Peterson, Ph.D., senior vice president, biology

• Florence Lorget, Pharm.D., Ph.D., senior vice president, development sciences

• Will Liu, M.H.A., vice president, portfolio and program

• Varun Malhotra, M.D., MBA, vice president, clinical development

• Pam Henderson, R.N., B.S.N., vice president, clinical operations

• Jonathan Kim, MBA, vice president, corporate development

• Brian Cuneo, J.D., CXO/CLO and senior partner, ARCH Venture Partners

Board of Directors: 

• Jason Ehrlich, M.D., Ph.D., board member, co-founder and CEO

• Paul Berns, board chair and managing director, ARCH Venture Partners

• Jason Coloma, Ph.D., co-founder, board member and CEO, Maze Therapeutics

• Alaa Halawa, board member and head of healthcare, Mubadala Ventures

• Fred Cohen, M.D., D.Phil., board member and founder of Monograph Capital

• Travis Murdoch, M.D., co-founder, independent board member, CEO of Braveheart Bio and former CEO, HI-Bio

Scientific Advisory Board:

• Charles C. Wykoff, M.D., Ph.D., director of research at Retina Consultants of Texas; chairman of research, Retina Consultants of America and deputy chair of ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital

• Arshad M. Khanani, M.D., MA, FASRS, managing partner, director of clinical research, and director of fellowship at Sierra Eye Associates and clinical professor at the University of Nevada, Reno School of Medicine

• David Eichenbaum, M.D., FASRS, partner and director of research at Retina Vitreous Associates of Florida

• Margaret Chang, M.D., MS, senior partner, Retinal Consultants of Sacramento; member, Medical Leadership Board of Retinal Consultants of America

• Rishi Singh, M.D., staff surgeon, Cole Eye Institute, Cleveland Clinic and professor of ophthalmology at the Lerner College of Medicine in Cleveland Ohio; incoming chair of the Department of Ophthalmology at Mass General Brigham

• Veeral Sheth, M.D., MBA, FASRS, partner and director of clinical trials, University Retina; clinical assistant professor at the University of Illinois at Chicago

• Atul Dandekar, chief strategy and business officer of Maze Therapeutics and Ollin co-founder